Imbalance between protective (adiponectin) and prothrombotic (Plasminogen Activator Inhibitor-1) adipokines in metabolic syndrome.

[1]  Ji-Yun Hwang,et al.  Hypoadiponectinemia Is Strongly Associated with Metabolic Syndrome in Korean Type 2 Diabetes Patients , 2010, Journal of the American College of Nutrition.

[2]  S. R. Rao,et al.  The metabolic syndrome and associated risk factors in an urban industrial male population in South India. , 2010, The Journal of the Association of Physicians of India.

[3]  W. Sheu,et al.  Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan. , 2009, Archives of gerontology and geriatrics.

[4]  B. Khan,et al.  Metabolic syndrome and cardiovascular disease in South Asians , 2009, Vascular health and risk management.

[5]  S. R. Mahadik,et al.  Association of adiposity, inflammation and atherosclerosis: the role of adipocytokines and CRP in Asian Indian subjects. , 2008, Metabolic syndrome and related disorders.

[6]  J. Beilby,et al.  Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity , 2008, International Journal of Obesity.

[7]  H. Itoh,et al.  High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. , 2007, Metabolism: clinical and experimental.

[8]  G. Sypniewska.  Pro-Inflammatory and Prothrombotic Factors and Metabolic Syndrome , 2007, EJIFCC.

[9]  T. Langmann,et al.  High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. , 2007, Biochemical and biophysical research communications.

[10]  P. Scherer.  Adipose Tissue , 2006, Diabetes.

[11]  J. Ruige,et al.  Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome , 2006, International Journal of Obesity.

[12]  Y. Hattori,et al.  RETRACTED ARTICLE: Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats , 2005, Diabetologia.

[13]  V. Mohan,et al.  Association of low adiponectin levels with the metabolic syndrome--the Chennai Urban Rural Epidemiology Study (CURES-4). , 2005, Metabolism: clinical and experimental.

[14]  B. Balkau,et al.  The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. , 2003, Diabetes & metabolism.

[15]  J. Marsh.  Lipoprotein metabolism in obesity and diabetes: insights from stable isotope kinetic studies in humans. , 2003, Nutrition reviews.

[16]  P. Morange,et al.  Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk , 2003, Journal of thrombosis and haemostasis : JTH.

[17]  Rajeev Gupta,et al.  Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. , 2003, Diabetes research and clinical practice.

[18]  Ambady Ramachandran,et al.  Metabolic syndrome in urban Asian Indian adults--a population study using modified ATP III criteria. , 2003, Diabetes research and clinical practice.

[19]  T. Tai,et al.  Plasma adiponectin levels in overweight and obese Asians. , 2002, Obesity research.

[20]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[21]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[22]  A. Hamsten,et al.  Very Low-Density Lipoprotein Activates Nuclear Factor-κB in Endothelial Cells , 1999 .

[23]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[24]  G. Reaven,et al.  Pathophysiology of insulin resistance in human disease. , 1995, Physiological reviews.

[25]  M. Alessi,et al.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis , 1991, Diabetologia.

[26]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[27]  M. Alessi,et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.

[28]  M. K. Garg,et al.  Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome , 2012, Indian journal of endocrinology and metabolism.

[29]  L. Duvnjak,et al.  The metabolic syndrome - an ongoing story. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[30]  L. Shatilina,et al.  [Adiponectin: lowering in metabolic syndrome and independent relation to hypertriglyceridemia]. , 2008, Kardiologiia.

[31]  D. Loskutoff,et al.  Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. , 1996, The Journal of clinical investigation.

[32]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.